RecruitingPhase 1NCT06957431

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Studying Leiomyosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Washington University School of Medicine
Principal Investigator
Mia C Weiss, M.D.
Washington University School of Medicine
Intervention
Zanzalintinib(drug)
Enrollment
18 enrolled
Eligibility
18 years · All sexes
Timeline
2025 – 2033

Study locations (1)

Collaborators

Exelixis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06957431 on ClinicalTrials.gov

Other trials for Leiomyosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Leiomyosarcoma →

← Back to all trials